drugset / Trial / NCT04584684

Mouth Rinses for Inactivation of COVID-19

NCT04584684

Phase 2 Terminated 128 enrolled University of North Carolina, Chapel Hill
RandomizedParallel-groupTriple-blindTreatment

Summary

Randomized, double-blind prospective trial to test the efficacy and acceptability of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 480 subject participants and one, 75-90 minute visit.

Timeline

Start
2020-12-18
Primary completion
2021-10-21
Completion
2021-10-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alcohol Other / unclassified 10 ml Other
Comparator Alcohol Other / unclassified 27 % Other
Comparator Cetylpyridinium Small molecule 0.075 %
Comparator Cetylpyridinium Small molecule 10 ml
Comparator Chlorhexidine Small molecule 0.12 % Other
Comparator Chlorhexidine Small molecule 10 ml Other
Comparator Hydrogen Peroxide Small molecule 1.5 % Other
Comparator Hydrogen Peroxide Small molecule 10 ml Other
Comparator Povidone-iodide Unknown 0.5 % Other
Comparator Povidone-iodide Unknown 10 ml Other

Indications